Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biocryst Pharma Inc (BCRX)

Biocryst Pharma Inc (BCRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,184,003
  • Shares Outstanding, K 178,870
  • Annual Sales, $ 17,810 K
  • Annual Income, $ -182,810 K
  • 60-Month Beta 2.48
  • Price/Sales 112.27
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BCRX with:

Options Overview Details

View History
  • Implied Volatility 71.80%
  • Historical Volatility 54.20%
  • IV Percentile 25%
  • IV Rank 12.40%
  • IV High 165.66% on 02/01/21
  • IV Low 58.52% on 09/27/21
  • Put/Call Vol Ratio 0.35
  • Today's Volume 3,467
  • Volume Avg (30-Day) 7,065
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 148,098
  • Open Int (30-Day) 155,871

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.32
  • Number of Estimates 5
  • High Estimate -0.27
  • Low Estimate -0.38
  • Prior Year -0.34
  • Growth Rate Est. (year over year) +5.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.72 +14.18%
on 12/06/21
13.27 -7.76%
on 11/10/21
+0.02 (+0.16%)
since 11/08/21
3-Month
10.72 +14.18%
on 12/06/21
16.12 -24.07%
on 09/14/21
-2.72 (-18.18%)
since 09/08/21
52-Week
6.83 +79.21%
on 12/22/20
18.48 -33.77%
on 08/06/21
+4.58 (+59.79%)
since 12/08/20

Most Recent Stories

More News
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation...

BCRX : 12.24 (+0.25%)
BioCryst (BCRX) Begins Enrollment in PNH Study on BCX9930

BioCryst (BCRX) starts patient enrollment in the pivotal REDEEM-2 study evaluating BCX9930 for treating patients with paroxysmal nocturnal hemoglobinuria.

BCRX : 12.24 (+0.25%)
SRPT : 86.02 (+0.81%)
VTVT : 1.1900 (+3.48%)
EDIT : 31.90 (+3.00%)
BioCryst Begins Patient Enrollment in REDEEM-2 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH

RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first...

BCRX : 12.24 (+0.25%)
Royalty Pharma Acquires Additional Royalty Interests in BCX9930 and ORLADEYO from BioCryst Pharmaceuticals

Provides funding for BCX9930/oral Factor D program across multiple indicationsAgreements supported by strength of ORLADEYO® (berotralstat) launch and...

RPRX : 39.16 (+1.58%)
BCRX : 12.24 (+0.25%)
BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets

—Provides funding for BCX9930/oral Factor D program across multiple indications— —Agreements supported by strength of ORLADEYO® (berotralstat) launch and...

BCRX : 12.24 (+0.25%)
BioCryst Presents New Data Showing Sustained Reduction of HAE Attack Rates and Improved Patient Satisfaction After Patients Switch to ORLADEYO® (berotralstat)

Data from APeX-S showed patients had more than 80 percent attack free months after switching to ORLADEYO from injectable prophylactic therapies...

BCRX : 12.24 (+0.25%)
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of -10.00% and 8.59%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

BCRX : 12.24 (+0.25%)
BioCryst Reports Third Quarter 2021 Financial Results and Upcoming Key Milestones

—3Q 2021 revenue of $41.0 million— —ORLADEYO® (berotralstat) net revenue of $37.0 million— —Full year 2021 ORLADEYO net revenue expected to be...

BCRX : 12.24 (+0.25%)
Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BCRX : 12.24 (+0.25%)
BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...

BCRX : 12.24 (+0.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential...

See More

Key Turning Points

3rd Resistance Point 12.97
2nd Resistance Point 12.70
1st Resistance Point 12.47
Last Price 12.24
1st Support Level 11.97
2nd Support Level 11.70
3rd Support Level 11.47

See More

52-Week High 18.48
Fibonacci 61.8% 14.03
Fibonacci 50% 12.65
Last Price 12.24
Fibonacci 38.2% 11.28
52-Week Low 6.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar